KRAS and non-small cell lung carcinoma: A post‐hoc analysis of KEYNOTE‐042 (first‐line Pembrolizumab monotherapy vs. chemotherapy in PD‐L1 positive advanced NSCLC) showed that patients with KRAS alterations had better PFS compared to those without KRAS alterations (median PFS: 12 months [n = 30] vs. 6 months [n = 127]).8